Cortechs.ai Secures Series C Funding to Expand AI-Powered Neuroimaging and Prostate Imaging Solutions

Company Name: Cortechs.ai
Location: San Diego, CA
Sector: AI in Medical Imaging

Funding Details:

• Funding Round: Series C
• Lead Investor: VILAS Ventures

Purpose of Funding:
The capital will be used to:

• Accelerate the rollout of new product features.
• Broaden commercial footprint globally.
• Drive ongoing research and development efforts.

Leadership:

• Kyle Frye, CEO

About Cortechs.ai:
Cortechs.ai is at the forefront of AI applications in radiology, leveraging advanced medical imaging technologies to enhance disease screening and early detection. Its goal is to enable longer, healthier lives for patients through earlier and more accurate diagnoses.

Key Offerings:
Cortechs.ai develops and markets medical device software designed for:

• Neurodegenerative Disease Management: Quantifies and tracks neurodegenerative diseases such as Alzheimer’s, epilepsy, multiple sclerosis, and brain trauma.
• Cancer Detection: Assists in identifying clinically significant prostate cancer.

Clinical Impact:
The company’s brain imaging software equips radiologists, neurologists, oncologists, and clinical researchers with tools to assess and monitor brain abnormalities in a cost-effective and efficient manner.

Regulatory Milestones:
Cortechs.ai’s products are FDA-cleared and play a critical role in the diagnosis and follow-up of:

• Neurodegenerative and traumatic brain conditions.
• Prostate cancer.

Looking Ahead:
Cortechs.ai aims to expand its reach and continue its mission of transforming radiology through AI-powered innovation, benefiting healthcare providers and patients worldwide.